[Angiogenesis: a new therapeutic target of thoracic and laryngopharyngeal carcinoma].
Angiogenesis or new blood vessel formation is a complex and fundamental event in the process of tumor growth and metastatic dissemination. Actually, most of antiangiogenic agents target the VEGF considered like the most potent proangiogenic factor. These molecules directly inhibit VEGF or the kinase activity of its receptor (VEGFR) and represent a significant therapeutic progress in several solid tumors types. First clinical studies of antiangiogenic agents in thoracic and laryngopharyngeal carcinomas have shown promise mainly in combination with other therapies (chemotherapy, other targeted therapies or radiotherapy). Besides common antiangiogenic therapies-induced adverse events, risks of bleeding caused by tumor necrosis mainly in squamous cell lung carcinomas have been observed during early clinical trials. Assessment of surrogate markers of target inhibition could allow a better selection of patients able to benefit from antiangiogenic treatments eventually combined with chemotherapy or molecules targeting others metabolic pathways.
Service de Pneumologie, Hôpital de la Pitié-Salpêtrière, 47-83 Boulevard de l'Hôpital, 75013 Paris, France. laurent.taillade@psl.aphp.fr
L
L
Taillade
I
I
Alexandre
B
B
Billemont
J-B
JB
Meric
V
V
Sultan-Amar
O
O
Rixe
D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D006801:Humans; D007822:Laryngeal Neoplasms / Q000098:blood supply / Q000188:drug therapy; D008175:Lung Neoplasms / Q000098:blood supply* / Q000188:drug therapy; D008654:Mesothelioma / Q000098:blood supply / Q000188:drug therapy; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D010039:Otorhinolaryngologic Neoplasms / Q000098:blood supply* / Q000188:drug therapy; D010610:Pharyngeal Neoplasms / Q000098:blood supply / Q000188:drug therapy; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D042461:Vascular Endothelial Growth Factor A; D040262:Receptors, Vascular Endothelial Growth Factor